Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Raw Materials (2023 - 2025)

Historic Raw Materials for Verrica Pharmaceuticals (VRCA) over the last 3 years, with Q2 2025 value amounting to $1.0 million.

  • Verrica Pharmaceuticals' Raw Materials fell 1227.15% to $1.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.0 million, marking a year-over-year decrease of 1227.15%. This contributed to the annual value of $1.1 million for FY2024, which is 15761.9% up from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Raw Materials stood at $1.0 million for Q2 2025, which was down 1227.15% from $1.0 million recorded in Q1 2025.
  • Verrica Pharmaceuticals' 5-year Raw Materials high stood at $1.2 million for Q3 2024, and its period low was $116000.0 during Q3 2023.
  • For the 3-year period, Verrica Pharmaceuticals' Raw Materials averaged around $897375.0, with its median value being $1.1 million (2024).
  • Its Raw Materials has fluctuated over the past 5 years, first soared by 94137.93% in 2024, then tumbled by 1227.15% in 2025.
  • Quarter analysis of 3 years shows Verrica Pharmaceuticals' Raw Materials stood at $420000.0 in 2023, then skyrocketed by 157.62% to $1.1 million in 2024, then decreased by 6.84% to $1.0 million in 2025.
  • Its Raw Materials was $1.0 million in Q2 2025, compared to $1.0 million in Q1 2025 and $1.1 million in Q4 2024.